Serum Level of MMP-3 and MMP-9 in Patients with Diabetes Mellitus Type 2 Infected with Epstein-Barr Virus

被引:4
|
作者
Stepien, Ewa [1 ]
Dworzanski, Jakub [2 ]
Dworzanska, Anna [2 ]
Drop, Bartlomiej [3 ]
Polz-Dacewicz, Malgorzata [1 ]
机构
[1] Med Univ Lublin, Dept Virol, SARS Lab, PL-20093 Lublin, Poland
[2] Masovian Specialist Hosp, PL-26617 Radom, Poland
[3] E Hlth Lab, Dept Comp Sci & Med Stat, PL-20090 Lublin, Poland
关键词
diabetes mellitus type 2; EBV; MMP-3; MMP-9; MATRIX METALLOPROTEINASES; PREVALENCE; OBESITY; TISSUE;
D O I
10.3390/ijms232113599
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetes mellitus type 2 (DM2) has recently become one of the most important health problems in the world. Patients with DM2 with long-term glycaemia are more likely to become infected than the healthy population. Matrix metalloproteinases (MMPs) play a key role in tissue remodeling during various physiological processes. However, it has been reported that certain MMPs are overexpressed during the development of various human diseases. In this study, we analyzed the levels of MMP-3 and MMP-9 in the serum of DM2 patients with and without Epstein-Barr virus (EBV) infection. The study included 115 patients with DM2 hospitalized in the Internal Ward of the Masovian Specialist Hospital in Radom, Poland, who were divided into two groups: EBV-positive and EBV-negative. The levels of MMP-3 and MMP-9 were tested in the serum of patients using the ELISA method, while the presence of EBV in saliva was tested by polymerase chain reaction (PCR). The presented studies showed a significant difference in the concentration of both MMPs in diabetic patients additionally infected with EBV compared to the group of non-infected individuals. It seems that MMPs may be useful biomarkers in the diagnosis, prognosis, and monitoring of diabetes associated with EBV infection.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Glutamic Acid Decarboxylase Antibodies in patients with diabetes Type 2 Epstein-Barr virus-related Infection
    Jasim, Majid Hadi
    Abbas, Heider Hemeed
    Al-Khateeb, Sumaya Najim
    Yasir, Saif Jabbar
    Hasan, Amal Merza
    Atyaa, Fatin Naji
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2020, 14 (02): : 935 - 940
  • [22] Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis
    Pawlak, Krystyna
    Mysliwiec, Michal
    Pawlak, Dariusz
    CLINICAL BIOCHEMISTRY, 2011, 44 (10-11) : 838 - 843
  • [23] CORRELATION STUDY BETWEEN SERUM MMP-2, MMP-9, CASPASE-3 AND LIPOPROTEIN(A) LEVELS AND INTRACRANIAL ANEURYSMS
    Huang, Yong-kai
    Han, De-qing
    Bao, Zheng-jun
    Zhu, Xiao-peng
    Yuan, Wen
    ACTA MEDICA MEDITERRANEA, 2019, 35 (02): : 1163 - 1167
  • [24] Relationship between serum MMP-9 level and prognosis after radical resection for Hilar cholangiocarcinoma patients
    Li, Ou
    Yi, Weimin
    Yang, Pingzhou
    Guo, Chao
    Peng, Chuang
    ACTA CIRURGICA BRASILEIRA, 2019, 34 (04)
  • [25] Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy
    Kapelko-Slowik, Katarzyna
    Slowik, Miroslaw
    Szalinski, Marek
    Dybko, Jaroslaw
    Wolowiec, Dariusz
    Prajs, Iwona
    Bohdanowicz-Pawlak, Anna
    Biernat, Monika
    Urbaniak-Kujda, Donata
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 27 (01): : 99 - 103
  • [26] Expression of Metalloproteinases MMP-2 and MMP-9 in Sentinel Lymph Node and Serum of Patients with Metastatic and Non-Metastatic Breast Cancer
    Daniele, A.
    Zito, A. F.
    Giannelli, G.
    Divella, R.
    Asselti, M.
    Mazzocca, A.
    Paradiso, A.
    Quaranta, M.
    ANTICANCER RESEARCH, 2010, 30 (09) : 3521 - 3527
  • [27] Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma
    Kuyvenhoven, JP
    van Hoek, B
    Blom, E
    van Duijn, W
    Hanemaaijer, R
    Verheijen, JH
    Lamers, CBHW
    Verspaget, HW
    THROMBOSIS AND HAEMOSTASIS, 2003, 89 (04) : 718 - 725
  • [28] Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels
    Preston, GA
    Barrett, CV
    Alcorta, DA
    Hogan, SL
    Dinwiddie, L
    Jennette, JC
    Falk, RJ
    NEPHRON, 2002, 92 (04): : 817 - 823
  • [29] Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
    Marx, N
    Froehlich, J
    Siam, L
    Ittner, J
    Wierse, G
    Schmidt, A
    Scharnagl, H
    Hombach, V
    Koenig, W
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) : 283 - 288
  • [30] The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction
    Wang, Shu-Jin
    Qu, Zhong-Sen
    Zhang, Qing-De
    Li, Liang
    Wang, Feng
    Zhang, Bin
    Wu, Bang-Li
    Zhao, Yu-Wu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (08): : 13017 - 13027